Shots:
Catherine Liao, Chief Strategy Officer of CardieX, discusses the recent partnership between CardieX’s subsidiary ATCOR and Datacubed Health
Catherine delves deep into the growing dependence on decentralized clinical trials in the healthcare community and cites a few challenges in the study that come with it
Catherine stresses the potential of SphygmoCor technology while discussing…
VIEWPOINTS
Shots:
Kyle Forcier, Sr. Director of Life Science Product Marketing at Model N, addresses the challenges of the 340B program and ways manufacturers can mitigate them and emerge stronger
340B, a US federal government plan, enables eligible healthcare organizations and covered entities to receive outpatient drugs from drug manufacturers at significantly low prices
Kyle recalls…
Shots:
Björn Mellgård Vice President and Global Program Lead, TTP Program, Takeda, shares insights from the P-III data of TAK-755 for the treatment of cTTP
Björn eloquently shares the highlights of the study design for TAK-755, safety and efficacy outcomes, and goes on to share an update from the P-IIIb continuation trial evaluating TAK-755
With…
Shots:
In an insightful interview with PharmaShots, Sujay Jadhav, CEO of Verana Health, discusses VeraSite, a recently launched subscription-based tool for clinical trial site selection
To gather real-world data, Verana Health leverages the VeraQ population health data engine and transforms the structured and unstructured data into curated disease-specific modules called QData
Currently available in the…
Shots:
Nathan McCutcheon, President, and Chief Executive Officer of Shionogi, shares the highlights of the recent acquisition of Qpex Biopharma by Shionogi
Nathan believes that Qpex’s specialized expertise and extensive experience in chemistry and molecular design are sure to strengthen and be useful for the combined antibiotic pipeline
The acquisition provides Shionogi exclusive development, manufacturing,…
Shots:
Robert Connelly, CEO of Elicio Therapeutics, shared his views on the aftermath of the merger between Elicio Therapeutics & Angion Biomedica Corp. The strategic merger is instrumental to further advance Elicio’s product candidates with a focus on advancing its proprietary lymph node targeting Amphiphile (AMP) technology to develop immunotherapies
Robert recapitulates data presented at ASCO…
Shots:
Samantha Kerr, Chief Scientific Officer, Merz Aesthetics shares insights from the topline data of Xeomin P-III studies and pivotal study evaluating Belotero Balance (+)
Samantha says, for Belotero Balance (+), Merz Aesthetics has already submitted the data as a supplemental Premarket Approval Application (sPMA) with the FDA and plans to submit the data as…
Shots:
During the initial part of conversation, Sergey discussed details about the BDTX-1535 and the trial design of the P-I study where 1535 is being investigated in NSCLC and GBM patients
He then discussed the insights drawn from the first 51 patients recruited in the dose escalation part of the P-I study
In the final…
Shots:
Ruud talked about the key findings from the new RWE data at ERA-EDTA'23 which demonstrated the staggeringly low rate of diagnosis in chronic kidney disease (CKD)
He then discussed the risk factors of CKD and the urgent need to act on the growing global burden of CKD and how this disease is impacting the…
Shots:
Ken gave a brief overview of the OTC marketing approval of Eroxon (MED3000) by the US FDA. He also talked about Eroxon’s mechanism of action and how it helps to treat erectile dysfunction
Later, he discussed the study design and results obtained from the clinical trial based on which the approval was granted. In…

